Praxis Precision Medicines Inc (PRAX) Implied Volatility Current

Tracking PRAX implied volatility helps you identify when options premiums on Praxis Precision Medicines Inc are historically cheap or expensive, and where the best trades are hiding. Praxis Precision Medicines Inc implied volatility reflects the market's expectation of future price movement: when PRAX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Praxis Precision Medicines Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For PRAX, tracking metrics like PRAX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on PRAX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy.

It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where PRAX implied volatility sits today versus where it has been. Our scanner ranks Praxis Precision Medicines Inc implied volatility against its historical range, surfaces extremes in PRAX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Praxis Precision Medicines Inc IV is rich or cheap — measure it, then act on it.